Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • NGene
    Junior Member
    • Feb 2011
    • 8

    CisGenome Analysis

    I could not find any topic committed to such a tool, therefore I decided to open a new one. In case it already exists, feel free to merge.

    I am handling some output sequences from Illumina GAII and trying to figure out how to analyze them.
    My ChIP is against histone modifications and I usually look at very large ditributions of signals (I would not call them "peaks", if you get what I mean).

    Now, I am trying to catch a good tool to analyze them and I was suggested to use CisGenome. I tried to figure out how it works, especially last updated feture (CisGenomev2) which is supposed to be quite easy and user friendly.
    However, when I include my sample and control and call for "peaks", I only get one peak, which I know cannot be true from other tools/observations.
    I must likely be doing some mistakes.

    If there someone who knows the tool, I will try to explain my issue.

    1) I am using genome database (hg18)
    2) I include my sample (high signal) and control (low signal)
    3) I then select the parameters:

    # Read Extension Length E: 150 (what am I supposed to use here?)
    # Bin Size B: 500 (I tried to increase over 3000)
    # Half Window Size W: 1
    # Max Gap: 50
    # Min Peak: 100
    # Standardize Windows Statistics: checked (what am I supposed to use here?)
    # Win Stat Cutoff >= 3 (what am I supposed to use here?)
    # Apply Local Read Sampling Rate Filter: checked (I tried with and w/o this with no differences in the output)

    ## Local Rate Window: 10000
    ## Local Rate Cutoff: 1e-005

    # Boundary Refinement: checked

    ## Boundary Resolution: 5

    4) I start the search and it turns out only one peak in a place where I know the signal is high.

    I wonder how this can be possible.
    My sample and control differ a lot in terms of reads. Namely, the control has a lower depth. Does this influence the readout?

    I apologise for the long and complicated post, I hope someone can help.

    Thanks in advance.
  • wenliang
    Junior Member
    • Mar 2011
    • 1

    #2
    I am not an expert. My opinion is only for your reference.

    1.Win Stat Cutoff >= 3 (what am I supposed to use here?)
    the number is based on the exploration result. negbinomial_exp/obs<10%
    2. For boundary refinement: I don't checked if I do histone modifications thinking histone modification is different from TF binding that TF binding needs two strand while histone modification could be on single strand. but I may be wrong.

    Comment

    • mudshark
      Senior Member
      • Jan 2009
      • 138

      #3
      Before tweaking software parameters it might actually be helpful to look at the raw genomic read coverage to confirm that the raw data looks as expected, in your case containing broad regions of enrichment (relative to control). Otherwise you try to get something from the software that your data does not provide.

      How many mapped reads do you have? The difference in reads will matter a lot, as it is not simple (i.e. impossible) to normalize the read counts properly. Therefore you will probably get many false positives/negatives.

      Comment

      • NGene
        Junior Member
        • Feb 2011
        • 8

        #4
        Thanks a lot for the replies.

        I totally agree that tweaking should be the refining part. However, I think that even though the filtering cuts down lots of the reads, the total read numbers are pretty much similar among the samples:
        Code:
                raw           mapped       uniq. map.    non-redundant
        1a   39,462,703     29,738,325     24,113,845     22,722,389
        1b   37,286,139     28,958,710     23,448,540     21,408,884
        1c   39,499,025     29,346,076     24,366,428     22,060,482
        2a   33,161,351     26,928,919     22,220,217     17,646,007
        2b   36,682,484     28,621,303     23,846,721     20,401,399
        2c   39,406,479     28,787,186     24,292,959     17,977,853
        What do you think?

        Comment

        • ETHANol
          Senior Member
          • Feb 2010
          • 308

          #5
          I've gotten good output with SICER when looking at such data sets. Follow their advice on installing Numpy and Scipy in the ReadMe.txt. Other then that it was pretty easy to get running.

          --------------
          Ethan

          Comment

          Latest Articles

          Collapse

          • SEQadmin2
            Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
            by SEQadmin2


            Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

            The systematic characterization of the human proteome has
            ...
            07-20-2026, 11:48 AM
          • SEQadmin2
            Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
            by SEQadmin2



            Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
            ...
            07-09-2026, 11:10 AM
          • SEQadmin2
            Cancer Drug Resistance: The Lingering Barrier to Rising Survival
            by SEQadmin2



            Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

            There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
            07-08-2026, 05:17 AM

          ad_right_rmr

          Collapse

          News

          Collapse

          Topics Statistics Last Post
          Started by SEQadmin2, 07-20-2026, 11:10 AM
          0 responses
          9 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 07-13-2026, 10:26 AM
          0 responses
          30 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 07-09-2026, 10:04 AM
          0 responses
          41 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 07-08-2026, 10:08 AM
          0 responses
          26 views
          0 reactions
          Last Post SEQadmin2  
          Working...